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Abstract 
This pilot study aimed to explore relationships between metabolic and lung functions in 
patients with schizophrenia. Eighty patients with schizophrenia (55♂; 36.8±10.0 years) 
underwent a spirometry, were screened for metabolic syndrome (MetS), performed a 6-minute 
walk test (6MWT), and completed the International Physical Activity Questionnaire and the 
Psychosis evaluation tool for common use by caregivers. Patients with MetS (according to the 
International Diabetes Federation criteria) (n=28; 35%) had a reduced predicted forced 
expiratory volume for 1 second (77.4±13.2 versus 87.3±12.1%) and predicted forced vital 
capacity (75.3±11.1 versus 85.4±11.4%). Significantly more patients with MetS were 
diagnosed with restrictive lung dysfunction (RLD) (according to the Global Initiative for 
Chronic Obstructive Lung Disease criteria) (13 versus 8). Schizophrenia patients with RLD 
(n=21; 26.2%) had a significantly larger waist circumference (90.7±12.5 versus, 
105.6±14.7cm), were less physically active (653.6±777.9 versus 1517.9±1248.7 metabolic 
equivalent-min/week) and walked less on the 6MWT (502.6±92.3 versus 612.4±101.2m) than 
patients without RLD. The present data suggest that in patients with schizophrenia RLD 
might be associated with metabolic dysfunctions. Further prospective analyses are required to 
elucidate the complex interrelationships between lung and metabolic functions in patients 
with schizophrenia. 
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1. Introduction 
Both in the general population (Hole et al., 1996; Sin et al., 2005) and also in patients with 
schizophrenia, an impaired lung function is associated with higher cardiovascular risk and 
increased mortality (Himelhoch et al., 2004; Hoang et al., 2011; Martens et al., 2013). 
Impaired lung function is a generic term that includes two different spirometric patterns, 
obstructive lung dysfunction and restrictive lung dysfunction (Mannino et al., 2003a, 2005). 
Obstructive lung dysfunction is diagnosed in the presence of a forced expiratory volume for 1 
second / forced vital capacity (FEV1/FVC) ratio below 0.70, and classified according to 
FEV1expressed as percent of the predicted value (FEV1%) (GOLD, 2013). Conversely, 
restrictive lung dysfunction is characterized by a proportionally comparable decrease of both 
FEV1% and FVC expressed as percent of the predicted value (FVC%), consequently resulting 
in a normal FEV1/FVC ratio (Mannino et al., 2003a, 2005). 
Patients with schizophrenia are at an increased risk for obstructive and restrictive lung 
diseases (De Hert et al., 2011). For instance, the prevalence of restrictive lung disease may be 
present in up to half of individuals with schizophrenia (Aggarwal, 2012). However, currently 
the mechanisms that underlie the association between impaired lung function and increased 
cardio-metabolic mortality are largely unknown and they cannot be solely explained by the 
effects of smoking (Copeland et al., 2007; De Hert et al., 2011; Ozbulut et al., 2013). There is 
rigorous evidence in the general population that poor lung function is associated with insulin 
resistance and metabolic diseases (Ford & Mannino, 2004; Lin et al., 2006; Scarlata et al., 
2010, 2013). This is an important consideration for first-episode and multi-episode patients 
with schizophrenia, given that they have an increased risk of the metabolic syndrome (MetS) 
(Vancampfort et al., 2013a; Mitchell et al., 2013a & b). 
The mechanisms underlying any possible associations between lung function and 
metabolic risks are likely to be complex but warrant investigation. This may however include 
mechanical effects of central adiposity on lung function (Lessard et al., 2011), as well as 
inflammatory processes (Wannamethee et al., 2010) and unhealthy lifestyle factors (e.g. 
smoking and a sedentary lifestyle) (Vancampfort et al., 2013b) affecting both lung function 
and metabolic disease risk. To the best of our knowledge, no research has been conducted so 
far to examine whether patients with schizophrenia who have MetS are at an increased risk for 
obstructive and restrictive lung dysfunctions. It is also unclear whether, in the opposite way, 
there is a difference in metabolic profile between schizophrenia patients with and without 
lung dysfunctions. Therefore, the aim of this pilot study was to explore the relationships 
between metabolic and lung functions in patients with schizophrenia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Methods 
2.1. Participants and procedure 
Over a 6-month period, 100 in- and outpatients with a DSM-IV diagnosis of schizophrenia of 
the UPC KULeuven, campus Kortenberg and the Brussels Nighthospital Belgium were 
screened for participation. Six persons with co-morbid substance abuse were excluded while 
another six patients were excluded for a cardiovascular, locomotor or endocrine disorder that 
could prevent safe participation in a physical fitness test. Of the 88 eligible patients, another 8 
declined to participate.All participants were Caucasians. 
 
2.2. Demographical and anthropometric data 
The demographic data were obtained from medical records. All participants were asked 
whether they currently smoked. Those participants who responded affirmatively to this 
question were asked how many cigarettes they smoked per day. 
Body weight was measured in light clothing to the nearest 0.1kg using a SECA beam 
balance scale, and height to the nearest 0.1cm using a wall-mounted stadiometer.  
 
2.3. Spirometry 
Measurements of forced expiratory volume in 1sec (FEV1) and forced vital capacity (FVC) 
were obtained using spirometry (Micro, Cardinal Health, Chatham, UK) and following the 
American Thoracic Society guidelines (American Thoracic Society, 1995). Each participant 
completed two spirometry attempts while seated. Where the two readings differed by over 
100ml, a third measurement was taken. The tests were conducted by specially trained 
technicians.Values usedin this analysis included the FVC, the FEV1, and the FEV1/FVC 
ratio. Predicted values of FEV1 and FVC were determined using the normative reference 
equations for non-smoking Caucasians from Hankinson et al. (1999). Using the percentage of 
predicted FEV1, percentage of predicted FVC, and the FEV1-to-FVC ratio, we followed the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (2013) to classify 
participants as having chronic obstructive pulmonary disease (COPD). Participants were 
diagnosed with COPD if they had a FEV1-to-FVC ratio<0.70. Because too few participants 
were diagnosed with COPD (n=3), we were not able to divide them into categories of mild, 
moderate or severe COPD. In addition, we assigned participants as having restrictive lung 
disease (RLD) (FEV1-to-FVC ratio ≥0.70 and FVC <80% predicted). As per GOLD (2013) 
criteria, we assigned participants who met the criteria for having both COPD and RLD to the 
COPD group. 
 
2.4.  Metabolic syndrome  
All participants received a comprehensive metabolic screening including a 2-hour 75-g 
glucose load oral glucose tolerance test (OGTT) (De Hert et al., 2006; van Winkel et al., 
2006). Patients were initiated on an overnight fast and were monitored during the OGTT. 
Waist circumference (WC) was measured to the nearest 1cm at the level of the umbilicus and 
at the end of expiration with the participant upright and his/her hands by their side. Blood 
pressure was recorded twice in the sitting position after a five minute rest with an Omron M6 
(HEM-7001-E) (Omron® Healthcare Europe). The presence of MetS was assessed using the 
International Diabetes Federation criteria (Alberti et al., 2006).  
 
2.5. Physical fitness assessment 
Physical fitness was measured using the 6-minute walk test (6MWT) and according to the 
American Thoracic Society guidelines (American Thoracic Society, 2002) in an indoor 
corridor with a minimum of external stimuli. Two cones, 25m apart, indicated the length of 
the walkway. Participants were instructed to walk (without running or jogging) back and forth 
around the conesfor a total duration of six minutes. Resting was allowed if necessary, but 
walking was to be resumed as soon as the participants were able to do so. The protocol stated 
that the testing was to be interrupted if threatening symptoms appeared. The total distance 
walked in 6 minutes was recorded to the nearest decimetre. Standardised encouragements 
were provided at recommended intervals as per guideline instruction (American Thoracic 
Society, 2002). Supervision and measurement of the 6MWT was performed by one of four 
trained members (three physical therapists, one research nurse). In order to exclude any 
learning effects, the test was repeated within 3 days. The distance achieved on the second trial 
was included. With an intra class correlation of 0.96 [95% confidence interval (CI):0.94-
0.98)], the 6MWT has been shown to be a reliable test to assess the physical fitness in patients 
with schizophrenia (Vancampfort et al., 2011). 
 
2.6.Physical activity assessment 
The International Physical Activity Questionnaire (IPAQ) (Craig et al., 2003) was completed 
to evaluate the level of physical activity participation. The IPAQ uses a structured format that 
asks participants to recall activities for each of the last seven preceding days in morning, 
afternoon, and evening time periods. On the basis of what activities participants self-reported, 
the interviewer also clarified the perceived intensity of that specific activity. A continuous 
indicator was calculated as a sum of weekly metabolic equivalent (MET)-minutes per week of 
physical activity. The MET energy expenditure was estimated by weighting the reported 
minutes per week by a MET energy expenditure estimate for each type of activity (low, 
moderate and vigorous intensity physical activity). MET-levels were obtained from 
Ainsworth et al. (2000). The weighted MET-minutes per week were calculated as duration x 
frequency per week x MET-intensity, which were then summed to produce a weighted 
estimate of total physical activity from all reported activities per week. Previous research 
indicated that the IPAQ can be considered as a reliable surveillance tool to assess levels of PA 
in patients with schizophrenia (Faulkner et al., 2006; Soundy et al., 2014). 
 
2.7. Psychiatric symptoms 
Patients were assessed for psychiatric symptoms using the Psychosis evaluation tool for 
common use by caregivers (PECC) (De Hert et al., 1998). The semi-structured PECC-
interview evaluates 100 symptom items on a 7-pointscale. Symptoms are grouped in 5factors: 
positive, negative, depressive, cognitive and excitatory symptoms. In this study we only used 
the overall score. The total score ranges from 20 to 140 with higher scores indicating more 
severe psychopathology. Validation results (De Hert et al., 2002) suggest that the PECC can 
be successfully used for the evaluation of clinical symptoms in schizophrenia. 
 
2.8. Antipsychotic medication use 
Current antipsychotic medication use was recorded for each patient and converted into a daily 
equivalent dosage of chlorpromazine in accordance to the guidelines from Gardner et al. 
(2010). 
 
2.9. Statistical analyses 
Unpaired t tests with Bonferroni corrections for continuous variables and Fisher exact tests for 
categorical variables were used to examine differences in characteristics between patients 
with and without MetS and between patients with and without restrictive lung disease. All 
analyses were performed using SPSS (version 20.0). The study procedure was approved by 
the Scientific Committee of the UPC KU Leuven, Belgium. All participants gave their written 
informed consent. 
 
3. Results 
3.1. Patients’ characteristics 
Eighty patients with schizophrenia (55♂; 36.8±10.0 years; age range=18-58years) were 
included. Twenty-eight patients with schizophrenia (35%) fulfilled the criteria for MetS 
according to the International Diabetes Federation criteria (Alberti et al., 2006). Three patients 
with schizophrenia had a FEV1/FVC<0.70 which is the major criterion for a chronic 
obstructive pulmonary disease (COPD), while 21 patients fulfilled the criteria for restrictive 
lung disease (FEV1-to-FVC ratio ≥0.70 and FVC <80% predicted) (Global Initiative for 
Chronic Obstructive Lung Disease, 2013).  
 
3.2. Comparisons between patients with and without MetS  
As shown in Table 1, schizophrenia patients with MetS have a significantly reduced predicted 
FVC and FEV1 compared with schizophrenia patients without MetS. Significantly more 
patients with MetS were diagnosed with restrictive lung dysfunction. In contrast, no 
differences in the prevalence of obstructive lung dysfunction was observed between patients 
with and without MetS. The FEV1-to-FVC ratio did also not differ between schizophrenia 
patients without and without MetS. Finally, patients with MetS were significantly less 
physically active and performed significantly worse on the 6MWT than those without MetS. 
[Insert Table 1 about here] 
 
3.3. Comparisons between patients with and without restrictive lung disease 
Table 2 demonstrated that schizophrenia patients with restrictive lung disease had a 
significantly larger waist circumference than those without restrictive lung disease. No 
significant differences in other metabolic parameters were observed. Patients with restrictive 
lung disease were also significantly less physically active and performed significantly worse 
on the 6MWT than those without restrictive lung disease. 
[Insert Table 2 about here] 
 
4. Discussion 
4.1. General findings 
To the best of our knowledge, this pilot study is the first to demonstrate that in patients with 
schizophrenia the presence of MetS is associated with an increased prevalence of restrictive 
lung dysfunction (diagnosed as FEV1-to-FVC ratio ≥0.70 and FVC <80% predicted). While 
the presence of MetS (n=28; 35%) is in accordance with previous studies (Vancampfort et al., 
2013a; Mitchell et al., 2013a & b), the prevalence of RLD (n=21; 26.2%) in our study is 
lower than the 48% reported by Aggarwal (2012). A possible reason might be the higher age 
range between studies, which was 23 to 74 years in the study by Aggarwal (2012) and 18 to 
58 years in the present study. In contrast with an increased prevalence of RLD, the prevalence 
of COPD was not higher in the MetS group. The limited number of patients with COPD in 
our sample resulted in an insufficient power for detection of any association. Previous 
research in the general population (Ford & Mannino, 2004; Fimognari et al., 2007; Scarlata et 
al., 2013) showed that the restrictive, but not the obstructive respiratory pattern, is associated 
with MetS and insulin resistance, although data are conflicting (Lam et al., 2010) indicating 
that more research taking into account confounders such as smoking and physical activity is 
also needed here. 
As the MetS is unlikely to be a homogeneous entity (Gale, 2008), we explored 
differences in each of its components between patients with and without restrictive lung 
function impairment. Only waist circumference differed significantly between patients with 
and without RLD. The current preliminary data indicates that abdominal obesity might be an 
important determinant of the association between MetS and restrictive lung function 
impairment. Next to a possible mechanical obstacle to ventilation by visceral fat (Lessard et 
al., 2011), another reason might be that visceral fat produces pro-thrombotic and 
inflammatory mediators, including C-reactive protein, interleukin-6, and tumor necrosis 
factor-alpha (Ouchi et al., 2011).  
However, there are other mechanisms independent of abdominal obesity by which MetS 
might affect lung function (Mannino et al., 2003b). For example, pathological microvascular 
changes may affect gas transfer across the alveolar-capillary membrane (Chance et al., 2008). 
In patients with schizophrenia metabolic changes may result in weakened aerobic and 
peripheral and respiratory muscular fitness while somatic pain associated with pre-diabetes is 
associated with a sedentary lifestyle, which in turn may contribute to an increased risk for 
pulmonary dysfunctions (Vancampfort et al., 2012; 2013c). Within this study we did not 
collate data on gas transfer or respiratory muscle dysfunction which would have enabled us to 
generate conclusions with greater certainty. The current data, in contrast, demonstrated that 
patients with RLD are less physically active and have a lower physical fitness than patients 
without RLD. Third, state and trait inflammatory markers associated with schizophrenia are 
known to be elevated independent from abdominal obesity (Manu et al., 2014). However, it is 
still unclear in which way these inflammatory changes may influence the expression of 
pulmonary dysfunctions in patients with schizophrenia. 
 
4.2. Limitations  
Although our current findings in patients with schizophrenia fit well with the recent 
documentation in the general population that the prevalence of MetS is associated with 
restrictive lung impairment (Ford & Mannino, 2004; Lin et al., 2006; Leone et al., 2009; 
Scarlata et al., 2013), the findings need to be interpreted with caution because of some 
methodological limitations. First, the current pilot study had a small sample size making it 
difficult to generalize findings. Due to the limited number of patients with COPD we were not 
able to categorize these patients into classifications of mild, moderate or severe COPD. 
Second, the diagnosis of obstructive and restrictive patterns was made on the basis of low 
dynamic lung volumes while a definitive diagnosis of restrictive patterns would require the 
finding of decreased total lung capacity (Aaron et al., 1999). Therefore, it is possible that a 
few patients classified in the restrictive group had increased residual volume and, afterwards, 
normal total lung capacity. However, the GOLD-criteria have been found to have a high 
diagnostic accuracy versus a diagnosis of restrictive pattern based on total lung capacity 
measurement (Aaron et al., 1999). Third, the cross-sectional nature of our study means that it 
is impossible to infer causality or to specify the direction of effect. Fourth, we did not include 
parameters such as socio-economic status, educational level, duration of illness and treatment 
and smoking history in order to increase the external validity. Fifth, the reliance on self-
reported recall physical activity is a method that is prone to both systematic and random errors 
(Soundy et al., 2007 & 2014). 
 
4.3. Future research 
Confirmatory prospective analyses in larger and well-defined samples are required to 
elucidate a causal pathway between lung function parameters and metabolic variables. In 
particular a confirmatory analysis in a drugs-naïve and smoking-free population is needed in 
order to avoid the confounding factor of antipsychotic treatment and smoking. Such studies 
need also accurate characterization of restrictive lung dysfunction, adiposity and possible 
confounders such as physical fitness and physical activity. In addition, research should 
acquire information on the measurement of the diffusing capacity of the lungs for carbon 
monoxide, gas exchange parameters, inflammatory markers, respiratory muscle strength, 
plasmatic insulin and c-peptide levels. 
In conclusion, our data suggest that in patients with schizophrenia the presence of MetS is 
associated with a restrictive lung dysfunction. Further prospective analyses to better elucidate 
the complex interrelationships between MetS and lung function parameters are highly needed. 
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Table  1. Comparisons in baseline characteristics between patients with schizophrenia with 
and without metabolic syndrome  
Data expressed as mean ± standard deviation, unpaired t-tests with Bonferroni corrections 
(*significant when p<0.006) for continuous variables and Fisher Exact tests for differences in 
gender distribution (p<0.05), MetS= metabolic syndrome, BMI = body mass index, FVC= 
forced vital capacity, FEV1=forced expiratory volume for 1 second, 6MWT= 6-minute walk 
test, IPAQ= International Physical Activity Questionnaire, MET= metabolic equivalent, 
PECC= psychosis evaluation tool for common use by caregivers, eq= equivalents, 
COPD=chronic obstructive pulmonary disease, RLD= restrictive lung disease. 
 
  
Variables Schizophrenia with 
MetS 
(n=28) 
Schizophrenia without MetS 
(n=52) 
P 
Gender (M/F) 18/10  37/15 0.61 
Age (years) 38.2±2.8 36.0±10.6 0.36 
BMI (kg/m²) 29.8±6.2 24.4±3.4 <0.001*
Smoking (cig/day) 17.9±15.0 13.1±14.5 0.18 
6MWT (m) 491.3±75.3 633.2±92.1 <0.001*
IPAQ (total MET-
min/week) 
709.3±675.3 1604.3±1307.7 <0.001*
PECC total 46.4±13.9 40.3±12.4 0.06 
Chlorpromazine eq 
(mg/day) 
828.5±492.0 612.4±333.8 0.04 
FVC (% predicted) 75.3±11.1 85.4±11.4 <0.001*
FEV1 (% predicted) 77.4±13.2 87.3±12.1 <0.001*
FEV1/FVC (%) 0.80±0.12 0.83±0.09 0.27 
Respiratory health    
   COPD (%) 
   RLD (%) 
2 (7.1%) 
13 (46.4%) 
1 (1.9%) 
8 (15.4%) 
0.28 
<0.001*
Table  2. Comparisons in baseline characteristics between patients with schizophrenia with 
and without restrictive lung disease  
Data expressed as mean ± standard deviation, unpaired t-tests with Bonferroni corrections (* 
significant when p<0.0038) for continuous variables and Fisher Exact tests for differences in 
gender distribution (p<0.05), MetS= metabolic syndrome, BMI = body mass index, 6MWT= 
6-minute walk test, IPAQ= International Physical Activity Questionnaire, MET= metabolic 
equivalent, PECC= Psychosis evaluation tool for common use by caregivers, eq= equivalents, 
COPD=chronic obstructive pulmonary disease, RLD= restrictive lung disease. 
 
 
Variables Schizophrenia with 
RLD 
(n=21) 
Schizophrenia without RLD 
(n=59) 
P 
Gender (M/F) 18/3 37/22 0.06 
Age (years) 37.9±9.6 35.0±10.1 0.25 
BMI (kg/m²) 29.0±7.2 25.3±4.4 0.04 
Smoking° (cig/day) 19.9±15.1 13.0±14.3 0.08 
6MWT (m) 502.6±92.3 612.4±101.2  <0.001*
IPAQ (total MET-
min/week) 
653.6±777.9  1517.9±1248.7  0.001* 
PECC total 44.9±12.2 41.6±12.0 0.41 
Chlorpromazine eq 
(mg/day) 
874.5±564.9  617.1±315.8  0.06 
Waist circumference (cm) 90.7±12.5 105.6±14.7  0.003* 
Systolic blood pressure 
(mmHg) 
120.1±14.1  122.3±11.6  0.61 
Diastolic blood pressure 
(mmHg) 
80.6±10.7  77.1±8.9  0.27 
Triglycerides (mg/dl) 140.5±83.3 127.7±71.8  0.61 
High density lipoproteins 
(mg/dl) 
59.3±28.9  52.8±15.3  0.42 
Fasting glucose (mg/dl) 89.2±14.5 85.8±10.2 0.42 
